Prof. Manuel Mayr and Dr. Marco Tognetti discussed how plasma proteomics is increasingly recognized as a fundamental approach to accelerate biomarker discovery and drug development, taking precision medicine to the next level.

Liquid biopsy, utilizing blood as a less invasive alternative for tissue samples, is becoming more and more prominent in precision medicine. The possibility to analyze blood samples across the species matrix makes mass spectrometry-based proteomics a powerful tool for early-stage, translational, and clinical research.

The integration of proteomics into the research pipeline helps to accelerate and de-risk drug development by bridging insights from the genotype and the phenotype to decode the complexity of disease pathways. Biognosys’ new and improved plasma biomarker discovery solution takes an unbiased and hypothesis-free approach to analyze the proteome beyond the expected. Starting from the complete proteome, the workflow identifies 3,000 of the most relevant proteins and an unlimited number of proteoforms in plasma and serum samples.

Prof. Manuel Mayr from King’s College London, discussed the importance of mass spectrometry-based plasma proteomics in cardiovascular and Covid-19 research. Marco Tognetti, PhD from Biognosys, demonstrated the application of Biognosys’ optimized plasma workflow in a pan-cancer study focused on identifying biomarker candidates from tissue leakage. Finally, Kanna Palaniappan, PhD from Freenome, shared perspectives on the value of unbiased proteomics for intelligent data analysis in early cancer detection.  The webinar concluded with a panel discussion, chaired by Biognosys CEO and co-founder Oliver Rinner, PhD.

Key Topics Include:

  • The importance of the plasma proteome in research and clinics
  • Advantages of mass spectrometry methods to analyze the plasma proteome
  • The application of Biognosys’ innovative plasma proteomics workflow in clinical research


To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.


Professor of Cardiovascular Proteomics
King's College London

Manuel Mayr qualified in Medicine from the University of Innsbruck (Austria) in 1999. He then moved to London to undertake a PhD. Upon completion of his PhD, he achieved promotion to Professor in 2011. He has been awarded a prestigious British Heart Foundation Personal Chair in 2017.

Principal Scientist

Marco Tognetti, Ph.D., is a principal scientist R&D at Biognosys. He is responsible for developing novel sample processing protocols, such as next-generation plasma depletion and immuno-peptide enrichment, and the improvement and automation of current ones.


Founder, CEO, Board Director. Oliver was co-founder of Biognosys in 2008 and is leading the company as CEO, starting as a spin-off from ETH Zurich to a market-leading inventor and provider of proteomics technology that Biognosys is today.

Staff Scientist

Kanna Palaniappan, Ph.D., is a staff scientist at Freenome, where he leads a research program focused on identifying protein biomarkers for early cancer detection, and translating those markers into clinical products.

Production Partner


Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making. Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. From our global headquarters just outside of Zurich, we operate one of the largest proteomics facilities worldwide and make the most advanced proteomics solutions available to life science researchers across industry and academia.

Additional Content From Biognosys

Spectronaut: Expand Biological Insights with DIA Proteomics

Spectronaut: Expand Biological Insights with DIA Proteomics

Data-independent acquisition (DIA) has become the method of choice for large-scale discovery proteomics. Its application for single-cell analysis promises to be more sensitive, robust, and reproducible than other proteomic approaches but is still a fairly unexplored territory.

Related Content